NCT01198119 2026-03-16
NBI-CAB
Centre Oscar Lambret
Phase 2 Terminated
Clinical Trials
170 trialsNCT03652298 2026-03-13
NeuroPrevPTSD
Centre Oscar Lambret
Phase 2 Terminated
NCT04268277 2026-02-27
Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
University of Ulm
Phase 2 Terminated
NCT06162351 2026-01-02
TOPOLOGY
Institut Curie
Phase 2 Terminated
NCT04964960 2025-10-31
Pembro+Chemo in Brain Mets
University of Kentucky
Phase 2 Terminated
NCT05513703 2025-10-24
A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie
Phase 2 Terminated
NCT03590652 2025-10-21
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
University of California, San Diego
Phase 2 Terminated
NCT04363801 2025-10-09
DisTinGuish
Leap Therapeutics, Inc.
Phase 2 Terminated
NCT05221320 2025-09-25
Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
BioMed Valley Discoveries, Inc
Phase 2 Terminated
NCT06175221 2025-09-15
Autologous TLPO Vaccine Basket
Elios Therapeutics, LLC
Phase 2 Terminated
NCT05678257 2025-09-12
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
NuCana plc
Phase 2 Terminated
NCT05101798 2025-07-28
The Role of 5-Aminolevulinic Acid Fluorescence-Guided Surgery in Head and Neck Cancers: a Pilot Trial
Icahn School of Medicine at Mount Sinai
Phase 2 Terminated
NCT05712174 2025-06-12
A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer
AHS Cancer Control Alberta
Phase 2 Terminated
NCT04830124 2025-06-10
ARTISTRY-6
Mural Oncology, Inc
Phase 2 Terminated
NCT07012330 2025-06-10
Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients
Erasmus Medical Center
Phase 2 Terminated
NCT06790303 2025-06-04
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2
GlaxoSmithKline
Phase 2 Terminated
NCT01871441 2025-05-16
Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Thomas Jefferson University
Phase 2 Terminated
NCT05972720 2025-05-15
FIRCE-1
CARGO Therapeutics
Phase 2 Terminated
NCT05177770 2025-05-08
Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer
Coherus Oncology, Inc.
Phase 2 Terminated
NCT01555489 2025-05-04
Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca
Thomas Jefferson University
Phase 2 Terminated
NCT00748709 2025-02-11
Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.
Boehringer Ingelheim
Phase 2 Terminated
NCT04305444 2025-01-08
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Zhejiang DTRM Biopharma
Phase 2 Terminated
NCT02944578 2024-10-29
Topical Curcumin for Precancer Cervical Lesions
Emory University
Phase 2 Terminated
NCT00811590 2024-09-19
Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome
University of Utah
Phase 2 Terminated
NCT04534283 2024-08-07
A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.
Indiana University
Phase 2 Terminated
NCT05016622 2024-07-31
Booster Dose Trial
Montefiore Medical Center
Phase 2 Terminated
NCT02842580 2024-07-10
HIGH-LIGHT
Federation Francophone de Cancerologie Digestive
Phase 2 Terminated
NCT02624388 2024-05-06
UVA-Gen001
University of Virginia
Phase 2 Terminated
NCT03472560 2024-04-09
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
Pfizer
Phase 2 Terminated
NCT01953926 2024-03-12
SUMMIT
Puma Biotechnology, Inc.
Phase 2 Terminated
NCT00019695 2024-03-04
Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT04337931 2024-02-13
A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma
Apexigen America, Inc.
Phase 2 Terminated
NCT05100316 2024-02-05
Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials
GlaxoSmithKline
Phase 2 Terminated
NCT04250805 2024-01-31
GASTROXY
Centre Hospitalier Universitaire de Saint Etienne
Phase 2 Terminated
NCT03297359 2024-01-23
WAVe
Ottawa Hospital Research Institute
Phase 2 Terminated
NCT04894994 2023-12-05
FLX475 in Combination With Ipilimumab in Advanced Melanoma
RAPT Therapeutics, Inc.
Phase 2 Terminated
NCT00931606 2023-09-13
MK-7962-012
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT03841760 2023-04-12
SUV on PSMA PET/CT in Non-Prostate Tumors
Sir Mortimer B. Davis - Jewish General Hospital
Phase 2 Terminated
NCT03582618 2023-01-10
CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma
TaiRx, Inc.
Phase 2 Terminated
NCT02576444 2022-12-28
OLAPCO
Yale University
Phase 2 Terminated
NCT04447235 2022-08-09
TITAN
Instituto do Cancer do Estado de SĂŁo Paulo
Phase 2 Terminated
NCT00394147 2022-08-05
Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer
Fox Chase Cancer Center
Phase 2 Terminated
NCT00746590 2022-07-21
Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma
BTG International Inc.
Phase 2 Terminated
NCT01320280 2022-07-01
BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer
Universitätsklinikum Hamburg-Eppendorf
Phase 2 Terminated
NCT00573131 2022-06-22
Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer
Boston Scientific Corporation
Phase 2 Terminated
NCT03713320 2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2 Terminated
NCT01606566 2022-02-18
A Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin for Recurrent Head and Neck Cancer.
PCI Biotech AS
Phase 2 Terminated
NCT00321100 2022-01-12
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
Fox Chase Cancer Center
Phase 2 Terminated
NCT00001880 2021-11-10
Stem Cell Transplantation for Metastatic Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00900562 2021-10-28
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
PharmaMar
Phase 2 Terminated